Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year

Available For Commercially Insured Patients By Mid-Month

With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.

Brown price tag on wooden background — Eisai determined Leqembi's "societal value" is as high as $37,600 but set its list price at $26,500 • Source: Shutterstock

Eisai Co., Ltd. and Biogen, Inc. will launch their amyloid protofibril-targeting antibody Leqembi (lecanemab), which won accelerated approval from the US Food and Drug Administration on 6 January for treatment of early Alzheimer’s disease, with a different approach to pricing than the partners used for their earlier anti-amyloid antibody, Aduhelm (aducanumab), which the FDA cleared a year and a half ago under the accelerated approval pathway but never gained traction with prescribers and payers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

28 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

25 Apr 2025

• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

25 Apr 2025

• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.